Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

Paige’s $100 million series C suggests investor enthusiasm for cancer diagnostics extends beyond liquid biopsy and includes machine-learning tools for image-based pathology. 

The New York-based company will use the funds to speed development of clinical applications, biomarkers and diagnostics and scale up marketing and adoption by labs and hospitals. The company plans to double its size, hiring about 70 people for its engineering and commercial teams...